ADXN
Addex Therapeutics Ltd (ADXN) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
ADXN’s R&D intensity is elevated versus diversified peers, which can support lower-carbon innovation but also raises near-term resource use and disclosure expectations.
The company’s very low leverage reduces balance-sheet pressure, which can improve resilience to environmental compliance costs relative to more indebted peers.
High gross margin suggests some operating efficiency, yet the available metrics do not show a clear peer-leading environmental footprint advantage.
No direct emissions, energy, water, or waste data were provided, limiting confidence that ADXN is structurally ahead of peers on core environmental metrics.
Social
R&D spending at 2.16% of revenue indicates continued investment in product development, which can support patient access and stakeholder trust versus slower-investing peers.
Stock-based compensation at 25.6% of revenue is high, which may align employee incentives but can also dilute perceived pay fairness relative to peers.
Low leverage reduces operational stress, which can help sustain workforce stability and service continuity compared with more financially constrained peers.
The absence of workforce, safety, turnover, and customer-outcome metrics prevents a stronger relative assessment of ADXN’s social positioning.
Governance
Debt-to-equity of 0.03 and net debt to EBITDA of 0.17 indicate conservative capital structure, which lowers creditor pressure and governance risk versus leveraged peers.
Stock-based compensation equal to 25.6% of revenue is a notable governance watchpoint, because it can signal heavier dilution risk than peers with tighter pay discipline.
Strong gross margin suggests pricing and operating discipline, but it does not substitute for board, audit, or shareholder-rights evidence needed to rank governance higher.
Without filing-based detail on board independence, executive incentives, and controls, ADXN appears broadly acceptable but not clearly superior to peers on governance.
Overall Score
ADXN appears broadly middle-of-pack versus peers, with low leverage supporting resilience, while limited disclosure and elevated stock-based compensation cap its ESG relative standing.
Score Driver: Limited Disclosure Across Core ESG Metrics Prevents A Stronger Peer-Relative Assessment.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Addex Therapeutics Ltd. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
